Gilead’s CAR-T therapy prolongs survival in key blood cancer trial – STAT News

Yescarta is the first CAR-T to show longer survival for this blood cancer in a randomized study, another milestone for the therapy.

Share on Facebook

Tweet

Follow us

Save